BRIEF-Uniqure Announces Preliminary Data On First Cohort In Phase I/IIA Clinical Trial Of AMT-260

June 19 (Reuters) - Uniqure NV UQ1.F:

  • UNIQURE ANNOUNCES PRELIMINARY DATA ON THE FIRST COHORT IN THE PHASE I/IIA CLINICAL TRIAL OF AMT-260 IN REFRACTORY MESIAL TEMPORAL LOBE EPILEPSY

  • UNIQURE NV - NO SERIOUS ADVERSE EVENTS REPORTED IN LOW-DOSE COHORT; ALL EVENTS MILD OR MODERATE

Source text: ID:nGNX8rqzZq

Further company coverage: UQ1.F


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.